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Abstract
Background
Persons with human immunodeficiency virus (HIV) who get and keep a suppressed viral
load are unlikely to transmit HIV. Simple, practical interventions to help achieve HIV viral
suppression that are easy and inexpensive to administer in clinical settings are needed. We
evaluated whether a brief video containing HIV-related health messages targeted to all
patients in the waiting room improved treatment initiation, medication adherence, and reten-
tion in care.
Methods and findings
In a quasi-experimental trial all patients (N = 2,023) attending two HIV clinics from June
2016 to March 2017 were exposed to a theory-based, 29-minute video depicting persons
overcoming barriers to starting treatment, taking medication as prescribed, and keeping
medical appointments. New prescriptions at index visit, HIV viral load test results, and dates
of return visits were collected through review of medical records for all patients during the 10
months that the video was shown. Those data were compared with the same variables col-
lected for all patients (N = 1,979) visiting the clinics during the prior 10 months (August 2015
to May 2016). Among patients exposed to the video, there was an overall 10.4 percentage
point increase in patients prescribed treatment (60.3% to 70.7%, p< 0.01). Additionally,
there was an overall 6.0 percentage point improvement in viral suppression (56.7% to
62.7%, p< 0.01), however mixed results between sites was observed. There was not a
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significant change in rates of return visits (77.5% to 78.8%). A study limitation is that, due to
the lack of randomization, the findings may be subject to bias and secular trends.
Conclusions
Showing a brief treatment-focused video in HIV clinic waiting rooms can be effective at
improving treatment initiation and may help patients achieve viral suppression. This feasi-
ble, low resource-reliant video intervention may be appropriate for adoption by other clinics
treating persons with HIV.
Trial registration
http://www.ClinicalTrials.gov (NCT03508310).
Introduction
Early initiation of antiretroviral therapy (ART) for patients infected with the human immuno-
deficiency virus (HIV) and subsequent lifelong viral suppression have important clinical and
prevention benefits. [1, 2] HIV treatment and prevention guidelines stress the importance of
HIV testing, linking persons diagnosed with HIV infection to care programs, and initiation and
maintenance of ART. [3–5] Despite these guidelines, a substantial number of persons with HIV
(PWH) in the United States have not been engaged in HIV care services. Centers for Disease
Control and Prevention (CDC) data from 2014 show that of the estimated 1.1 million PWH,
51% were not virally suppressed, [6] including an estimated 57% of black, 52% of Hispanic, and
43% of white PWH. Unsuppressed HIV infection, whether from lack of diagnosis, treatment, or
medication adherence, is the most important factor contributing to HIV incidence, currently
estimated at>35,000 new infections per year in the United States. [6] Although treatment initi-
ation, medication adherence, and retention in care are key for controlling HIV infection from
clinical and prevention perspectives, there are few evidence-based behavioral interventions to
support these behaviors, especially among black and Hispanic PWH.
CDC’s Compendium of Evidence-Based Interventions and Best Practices for HIV Prevention
has identified 24 interventions with varying levels of efficacy for improving either medication
adherence (N = 14) or retention in, linkage to, and re-engagement in HIV care (N = 11)
among PWH. [7] Whether delivered to individuals or groups, these interventions all require
multi-session attendance and relatively intensive organizational resources to implement.
There is a clear need for simple adherence and retention interventions that can be sustained at
relatively low cost and brought to scale quickly to achieve maximum patient coverage. [8]
Two widely disseminated video-based interventions, VOICES/VOCES (V/V) and Safe in the
City (SITC), were tested in sexually transmitted disease (STD) clinics and found to be cost-ben-
eficial and effective in reducing STD incidence. [9–14] It is therefore reasonable to expect that
a waiting room video having a similar format and user-informed development process as V/V
and SITC [15] would have a positive effect on HIV-related health outcomes and be acceptable
to both patients and clinic staff. The 25-minute V/V [11] and SITC [16] education-entertain-
ment videos are available in English and Spanish, can be viewed in clinic waiting rooms or
small group sessions, and comprise a set of intervention videos. Drawing on the successful
model developed for this set of videos, we created Taking Care of Me (TCOM), an intervention
video with supporting posters for use in HIV clinic waiting rooms. This paper describes its
impact on treatment initiation, medication adherence, and retention in care.
Effects of brief video on HIV patient treatment initiation and adherence
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Methods
We used a commercial institutional review board (IRB) because CDC was not involved in data
collection and none of the study sites had an affiliated IRB. On April 6, 2016 the IRB approved
the study with a waiver of informed consent since patients and providers would not be actively
recruited or surveyed, and only routinely collected data from each clinic’s EMR would be used
(S1 Appendix). The intervention was registered as a clinical trial after data collection began
because no participants were enrolled in the study. The authors confirm that all ongoing and
related trials for this intervention are registered.
IRB information:
Western Institutional Review Board | 1019 39th Avenue SE Suite 120 | Puyallup, WA
98374–2115 Office: (360) 252–2500 | Toll Free: (800) 562–4789 www.wirb.com
Study number: 1163249
Protocol number: 20160574
Online tracking: 11–434725
Trial registration: http://www.ClinicalTrials.gov (NCT03508310)
Patients and sites
To be eligible for participation, HIV clinics had to be located in a community with high AIDS
prevalence, use an electronic medical record (EMR) system, have a patient population that is
>55% black or African American (hereafter referred to as black) and/or Hispanic or Latino,
and agree not to participate in another behavioral intervention study during our study. Also,
the clinic’s population had to include >500 HIV-infected patients. Using these criteria, we
selected one HIV clinic in Huntsville, AL, another in Atlanta, GA and an HIV case manage-
ment center affiliated with an HIV clinic in Miami, FL. All patients visiting the clinics or center
during the 20-month study period were included in the study.
Intervention
The TCOM video follows the V/V and SITC model of incorporating key prevention messages
into dramatic soap-opera style content involving diverse characters. [16] Multiple script itera-
tions were reviewed by agency administrators, front-line providers, and consultants who were
PWH. TCOM’s conceptual framework incorporates Social Cognitive Theory, Information-
Motivation-Behavioral Skills model, and Social Action Theory, which together address cogni-
tive and behavioral factors related to study outcomes. [10, 11, 13] Storylines embedded preven-
tion messages aimed at increasing treatment initiation (n = 9), medication adherence (n = 35),
retention in care (n = 22), partner protection (n = 12), and communication with health care
providers (n = 7). The final script presented the prevention messages in dialog or visuals (e.g.,
taking medication with water instead of alcohol). The resulting 29-minute TCOM video
includes three vignettes and a 2-part animation about main characters who model overcoming
challenges to optimal HIV care. The video was played on continuous loop in recognition of
typically short patient wait times. Waiting room posters used images from TCOM to direct
patients’ attention to the video and reinforce prevention messages.
Study design
TCOM is a variant of videos with demonstrated efficacy in randomized control trials; there-
fore, we opted for a more resource- and time-efficient method to test our addition to this set of
videos. We used a quasi-experimental design, in which the intervention condition (i.e., TCOM
and posters) was implemented for 10 months (June 1, 2016-March 31, 2017) and the historical
Effects of brief video on HIV patient treatment initiation and adherence
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comparison condition (i.e., standard waiting room environment) was the prior 10-month
period (August 1, 2015-May 31, 2016). Funding for our study and difficulty in finding eligible
HIV clinics precluded use of contemporaneous controls. No patients were recruited and
enrolled in the study. Instead, routinely collected data were abstracted electronically from the
clinic EMRs for all patients age 18 and older who attended the clinic during the historical com-
parison period (retrospective data collected June 2016) and during the intervention period
(prospective data collected May 2017). Data were de-identified and included dates of index
and subsequent outpatient ambulatory medical care (OAMC) visits, sex, gender identity, race,
ethnicity, age at index visit, year of HIV diagnosis, date of first ART prescription at the clinic,
risks for HIV infection, and HIV viral load laboratory test dates and results.
Outcome measures
The primary study outcome was ART medication adherence. Adherence was measured by
whether viral load suppression (<200 RNA copies/mL) was achieved by 6 months (183 days)
after the patient’s index visit; undetectable viral load (<50 RNA copies/mL) also was assessed.
Primary outcome data were lab test results in patient EMRs. The secondary study outcomes
included treatment initiation and retention in HIV medical care. Treatment initiation was
measured by a patient’s receipt of an ART prescription on, before, or within 7 days after, their
index visit, as documented by OAMC visits in patient EMRs. Retention in HIV care was mea-
sured by an adaptation of the Health Resources and Services Administration’s (HRSA) defini-
tion in the Annual Ryan White HIV/AIDS Program Services Report (RSR): “all clients who
have had at least 2 or more OAMC visits for any reason at least 90 days apart in the past year
divided by all active clients who had had at least one such visit in the past year and are greater
than 12 years of age.” [17] HRSA’s definition is restricted to a calendar year; therefore, for
HRSA’s calculations, the first OAMC visits in the year must have occurred in the first 8
months (by September 1) of the measurement year in order to give patients an opportunity to
meet the retention criteria by year’s end (December 31). However, funding for our study only
allowed for a 10-month follow-up. To give patients time to meet retention criteria for our cal-
culations, their first OAMC visit must have occurred in the first 6 months of the study condi-
tion period. Our adapted formula comprised patients who came back after 90 days divided by
all patients who came in between 1–183 days.
Statistical analyses
Simplified sample size calculations were performed for rejecting the null hypothesis of equality
in the proportions of successes for the study’s primary outcome, assuming equal numbers of
patients in each period. These calculations correspond to an analysis using Fisher’s exact test
with a two-sided significance level of α = 0.05. We assumed if the true proportions of successes
for the two periods were 70% and 77% (historical comparison to intervention, 7 percentage
point absolute and 10% relative improvement), then sample sizes of 650 patients already pre-
scribed ART per period would be required to have 80% power to reject the null hypothesis.
Allowing for an annual attrition rate of 25%, sample sizes of 1157 patients per period would be
required to have 80% power to reject the null hypothesis.
We reviewed EMRs for all patients >17 years of age who had one or more OAMC visits
during either the historical comparison or intervention period (100% chart recovery from two
sites). Unfortunately, EMR data from the Miami site (all 650 patient records) were incomplete.
Miami uses a different EMR system than Huntsville and Atlanta, and important variables were
missing or could not be abstracted. Therefore, data from Miami were excluded from our analy-
ses. We analyzed all patients regardless of their exposure to the intervention video.
Effects of brief video on HIV patient treatment initiation and adherence
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We computed summary proportions for selected categorical socio-demographic variables
(sex/gender, race/ethnicity, age, HIV risk, and time since HIV diagnosis as assessed on index
visit date) by site for the comparison and intervention groups (Table 1). We did not statistically
test the equivalence of the composition of the comparison and intervention groups because
many patients were in both study periods. Simple proportions were used for assessing treat-
ment initiation (Table 2), and a 10-month adaptation of HRSA’s (which administers the Ryan
White HIV/AIDS Program) method for retention in care was used for that outcome (Table 3).
Time-to-event methods were used for assessing viral load suppression, as a proxy for medica-
tion adherence (Tables 4, 5, 6 and 7).
Planned primary analyses included outcomes of ART prescription within 7 days of index
visit (Table 2), follow-up OAMC visits during a study period (Table 3), and having suppressed
viral load (Tables 4 and 5). Subjects had one index visit per condition, and visits during one
condition could not be used for measurements in the other condition. For example, an OAMC
visit early in the intervention period was not counted toward retention for the comparison
period. A planned secondary analysis was having an undetectable viral load (Tables 6 and 7) as
an outcome. For binary outcomes, we computed proportions in the comparison and interven-
tion arms, the percentage point change with approximate 95% confidence intervals, and p-
Table 1. Characteristics of patients attending HIV clinics in two U.S. cities, August 1, 2015-March 31, 2017.
Comparison _______ Intervention _______
Characteristic Category Atlanta Huntsville Atlanta Huntsville
n (%) n (%) n (%) n (%)
All patients, N — 1327 653 1302 721
Sex/gender Male 1003 (75.8) 492 (75.3) 998 (76.8) 544 (75.5)
Female 299 (22.6) 155 (23.7) 279 (21.5) 166 (23.0)
Transgender 21 (1.6) 6 (0.9) 22 (1.7) 11 (1.5)
Race/ethnicity Black, non-Hispanic 1204 (90.7) 311 (47.6) 1176 (90.3) 347 (48.1)
Hispanic 32 (2.4) 40 (6.1) 29 (2.2) 43 (6.0)
White, non-Hispanic 63 (4.8) 291 (44.6) 61 (4.7) 316 (43.8)
Other 28 (2.1) 11 (1.7) 36 (2.8) 15 (2.1)
Age 18–24 years 27 (2.0) 40 (6.1) 53 (4.1) 60 (8.3)
25–34 years 468 (35.3) 202 (30.9) 441 (33.9) 225 (31.2)
35–87 years 832 (62.7) 411 (62.9) 808 (62.1) 436 (60.5)
HIV risk MSM 735 (55.4) 378 (57.9) 741 (56.9) 423 (58.7)
Heterosexual 475 (35.8) 234 (35.8) 477 (36.6) 254 (35.2)
IDU 31 (2.3) 28 (4.3) 30 (2.3) 24 (3.3)
MSM and IDU 20 (1.5) 4 (0.6) 20 (1.5) 5 (0.7)
Perinatal 1 (0.1) 4 (0.6) 1 (0.1) 4 (0.6)
Transfusion 0 (0.0) 2 (0.3) 3 (0.2) 2 (0.3)
Hemophilia 0 (0.0) 1 (0.2) 0 (0.0) 1 (0.1)
Not specified 65 (4.9) 2 (0.3) 30 (2.3) 8 (1.1)
Time since HIV < 1 year 156 (12.3) 77 (11.8) 135 (10.6) 92 (12.9)
diagnosis 1–5 years 483 (38.2) 208 (31.9) 475 (37.2) 217 (30.3)
6–10 years 321 (25.4) 161 (24.7) 341 (26.7) 170 (23.7)
> 10 years 305 (24.1) 207 (31.8) 327 (25.6) 237 (33.1)
Notes. Other race/ethnicity includes American Indian/Alaska Native, Asian, Pacific Islander/Native Hawaiian, multiple races, and not specified. MSM = men who have
sex with men. IDU = injection drug use.
Time since HIV diagnosis was assessed at index clinic visit date.
https://doi.org/10.1371/journal.pone.0204599.t001
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values for Fisher’s exact test. For time-to-event outcomes, we computed Kaplan-Meier propor-
tions at 183 days (6 months) in the comparison and intervention arms, the percentage point
change with approximate 95% confidence intervals, and p-values based on the normal
approximation.
We performed planned subgroup analyses to assess whether intervention effects varied by
clinic and by selected categorical socio-demographic variables (sex/gender, race/ethnicity, age,
HIV risk, and time since HIV diagnosis as assessed on index visit date). All analyses were per-
formed using SAS statistical software (version 9.4, SAS Institute, Inc., Cary, NC) and were con-
ducted by one author (CBB). All statistical tests were two-tailed. We did not adjust for the
overlap between the comparison and intervention groups, which tends to give conservative
significance tests assuming positive correlations between outcomes.
Results
There were a total of 4003 patients across both study conditions (Atlanta = 2629, Hunts-
ville = 1374) (Fig 1, S2 Appendix, Table 1). Of the patients in Atlanta 1706 were in one study
condition, and 923 (54.1%) were in both conditions. Of the patients in Huntsville 794 were in
one study condition, and 580 (73.0%) were in both conditions. Patient sex, gender identity,
and HIV risks were similar across sites and conditions. Compared to Atlanta, Huntsville had
Table 2. Proportion of antiretroviral therapy (ART) initiation among patients attending HIV clinics in two U.S. cities as measured by ART prescriptions written
before or within 7 days after index visit, August 1, 2015-March 31, 2017, by selected patient characteristics.
Comparison Intervention Percentage Point Change
(95% CI)
p-value
Characteristic Category m/n (%) m/n (%)
All patients, N — 1980 2023 — —
Clinic location Combined 1194/1980 (60.3) 1430/2023 (70.7) 10.4 (7.5, 13.3) <0.01
Atlanta 692/1327 (52.1) 788/1302 (60.5) 8.4 (4.6, 12.2) <0.01
Huntsville 502/653 (76.9) 642/721 (89.0) 12.2 (8.2, 16.1) <0.01
Sex/gender Male 877/1495 (58.7) 1069/1542 (69.3) 10.7 (7.3, 14.1) <0.01
Female 301/454 (66.3) 337/445 (75.7) 9.4 (3.5, 15.3) <0.01
Transgender 14/27 (51.9) 22/33 (66.7) 14.8 (-10.0, 39.6) 0.30
Race/ethnicity Black, non-Hispanic 875/1515 (57.8) 1027/1523 (67.4) 9.7 (6.3, 13.1) <0.01
Hispanic 43/72 (59.7) 56/72 (77.8) 18.1 (3.2, 32.9) 0.03
White, non-Hispanic 265/354 (74.9) 318/377 (84.4) 9.5 (3.7, 15.3) <0.01
Other 11/39 (28.2) 29/51 (56.9) 28.7 (9.1, 48.3) 0.01
Age 18–34 years 374/737 (50.7) 507/779 (65.1) 14.3 (9.4, 19.3) <0.01
35–87 years 820/1243 (66.0) 923/1244 (74.2) 8.2 (4.6, 11.8) <0.01
HIV risk Heterosexual 465/709 (65.6) 534/731 (73.1) 7.5 (2.7, 12.2) <0.01
MSM 655/1113 (58.9) 818/1164 (70.3) 11.4 (7.5, 15.3) <0.01
Other 74/158 (46.8) 78/128 (60.9) 14.1 (2.6, 25.6) 0.02
Time since HIV < 1 year 57/233 (24.5) 108/227 (47.6) 23.1 (14.6, 31.6) <0.01
diagnosis 1–5 years 440/691 (63.7) 496/692 (71.7) 8.0 (3.1, 12.9) <0.01
6–10 years 332/ 482 (68.9) 385/511 (75.3) 6.5 (0.9, 12.0) 0.03
> 10 years 356/512 (69.5) 434/564 (77.0) 7.4 (2.1, 12.7) 0.01
Notes. Other race/ethnicity includes American Indian/Alaska Native, Asian, Pacific Islander/Native Hawaiian, multiple races, and not specified. MSM = men who have
sex with men.
Injection drug use, MSM who inject drugs, hemophilia, transfusion, perinatal, not specified.
Time since HIV diagnosis was assessed at index clinic visit date.
m = all patients with an ART prescription before their index visit or within 7 days after their index visit (ART initiation). n = total patients in study period.
https://doi.org/10.1371/journal.pone.0204599.t002
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slightly more (4 percentage points) younger patients (18–24 year category) and somewhat
more (8 percentage points) patients who received their HIV diagnosis over 10 years ago. The
main difference between sites was race and ethnicity. Atlanta’s clinic population was 90%
black, while Huntsville’s was 48% black and 44% white. No adverse events were reported dur-
ing the study.
For HIV treatment initiation we found a significant (p< 0.01) overall increase of 10.4 per-
centage points between study periods and significant intervention effects at both sites.
Table 3. Proportion of retention in HIV medical care among patients attending HIV clinics in two U.S. cities as measured by any outpatient ambulatory medical
care visit after 3 months of follow-up from their index visit, August 1, 2015-March 31, 2017, by selected patient characteristics.
Comparison Intervention Percentage Point Change
(95% CI)
p-value
Characteristic Category m/n (%) m/n (%)
All patients, N — 1980 2023 — —
Clinic location Combined 1323/1709 (77.4) 1421/1804 (78.8) 1.4 (-1.4, 4.1) 0.35
Atlanta 803/1123 (71.5) 849/1153 (73.6) 2.1 (-1.5, 5.8) 0.26
Huntsville 520/586 (88.7) 572/651 (87.9) -0.9 (-4.5, 2.7) 0.66
Sex/gender Male 964/1278 (75.4) 1066/1370 (77.8) 2.4 (-0.9, 5.6) 0.15
Female 341/405 (84.2) 328/401 (81.8) -2.4 (-7.6, 2.8) 0.40
Transgender 15/22 (68.2) 24/30 (80.0) 11.8 (-12.3, 36.0) 0.35
Race/ethnicity Black, non-Hispanic 984/1302 (75.6) 1044/1353 (77.2) 1.6 (-1.7, 4.8) 0.34
Hispanic 53/63 (84.1) 61/67 (91.0) 6.9 (-4.4, 18.2) 0.29
White, non-Hispanic 271/316 (85.8) 285/346 (82.4) -3.4 (-9.0, 2.2) 0.24
Other 15/28 (53.6) 31/38 (81.6) 28.0 (5.8, 50.2) 0.03
Age 18–34 years 433/607 (71.2) 519/683 (76.0) 4.8 (-0.1, 9.6) 0.06
35–87 years 890/1101 (80.8) 902/1121 (80.5) -0.4 (-3.7, 2.9) 0.83
HIV risk Heterosexual 506/631 (80.2) 540/660 (81.8) 1.6 (-2.7, 5.9) 0.48
MSM 732/964 (76.0) 804/1037 (77.5) 1.6 (-2.1, 5.3) 0.43
Other 85/114 (74.6) 77/107 (72.0) -2.6 (-14.3, 9.1) 0.76
Time since HIV < 1 year 74/125 (59.2) 70/107 (65.4) 6.2 (-6.3, 18.7) 0.35
diagnosis 1–5 years 496/633 (78.4) 521/660 (78.9) 0.6 (-3.9, 5.1) 0.84
6–10 years 344/433 (79.4) 375/484 (77.5) -2.0 (-7.3, 3.4) 0.52
> 10 years 397/491 (80.9) 452/539 (83.9) 3.0 (-1.7, 7.7) 0.22
Notes. Other race/ethnicity includes American Indian/Alaska Native, Asian, Pacific Islander/Native Hawaiian, multiple races, and not specified. MSM = men who have
sex with men.
Injection drug use, MSM who inject drugs, hemophilia, transfusion, perinatal, not specified.
Time since HIV diagnosis was assessed at index clinic visit date.
m = all patients with an index visit and at least one outpatient ambulatory medical care visit for any reason after 90 days (retained in care). n = all patients who had at
least one outpatient ambulatory medical care visit for any reason between 0 and 6 months (183 days) in study period.
https://doi.org/10.1371/journal.pone.0204599.t003
Table 4. Proportion of medication adherence among patients attending HIV clinics in two U.S. cities as measured by laboratory-confirmed HIV viral suppression
(< 200 copies/ml) at 183 days or 6 months, August 1, 2015-March 31, 2017.
Comparison Intervention Percentage Point Change, %
(95% CI)
p-value
Characteristic Category % (95% CI) % (95% CI)
All patients, N — 1980 2023 — —
Clinic location Combined 56.7 (54.0, 59.4) 62.7 (60.3, 65.1) 6.0 (2.4, 9.6) <0.01
Atlanta 41.1 (37.8, 44.7) 58.7 (55.6, 61.8) 17.5 (12.9, 22.2) <0.01
Huntsville 77.7 (74.2, 81.1) 69.1 (65.4, 72.8) -8.6 (-13.7, -3.5) <0.01
https://doi.org/10.1371/journal.pone.0204599.t004
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(Table 2) Significant but differential intervention effects were observed for sex, race/ethnicity,
age, HIV risk exposure, and time since HIV diagnosis. Treatment initiation increased among
males (10.7 percentage points) and females (9.4 percentage points) between study periods
Table 5. Proportion of medication adherence among patients attending HIV clinics in two cities as measured by laboratory-confirmed HIV viral suppression
(< 200 copies/ml) at 183 days or 6 months, August 1, 2015-March 31, 2017, by subgroups of patient characteristics.
Atlanta Huntsville
Comparison Intervention Percentage Point
Change
p-value Comparison Intervention Percentage Point
Change
p-value
Characteristic Category % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Patients, N — 1327 1302 — — 653 721 — —
Clinic location — 41.1 (37.8,
44.7)
58.7 (55.6,
61.8)
17.5 (12.9, 22.2) <0.01 77.7 (74.2,
81.1)
69.1 (65.4,
72.8)
-8.6 (-13.7, -3.5) <0.01
Sex/gender Male 40.7 (36.7,
44.9)
57.5 (54.0,
61.1)
16.8 (11.4, 22.2) <0.01 75.7 (71.5,
79.8)
72.4 (68.1,
76.5)
-3.4 (-9.3, 2.5) 0.26
Female 42.6 (36.0,
49.8)
61.2 (54.6,
67.8)
18.6 (9.0, 28.1) <0.01 82.9 (76.3,
88.6)
59.5 (51.5,
67.6)
-23.5 (-33.7, -13.2) <0.01
Transgender 33.3 (12.2,
71.8)
70.4 (48.6,
89.2)
37.1 (-0.6, 74.8) 0.05 100 (100, 100) 63.6 (37.3,
88.8)
-36.4 (-64.8, -7.9) 0.01
Race/
ethnicity
Black, non-
Hisp
41.8 (38.3,
45.6)
58.3 (55.1,
61.6)
16.5 (11.6, 21.4) <0.01 74.3 (68.9,
79.4)
65.7 (60.2,
71.2)
-8.6 (-16.3, -0.9) 0.03
Hispanic 29.4 (13.4,
56.9)
76.0 (56.7,
91.3)
46.6 (18.3, 75.0) <0.01 87.7 (74.9,
95.8)
69.2 (54.6,
82.7)
-18.5 (-36.5, -0.5) 0.04
White, non-
Hisp
30.4 (18.5,
47.3)
53.6 (39.5,
69.1)
23.3 (2.4, 44.2) 0.03 79.7 (74.5,
84.5)
73.5 (68.0,
78.7)
-6.2 (-13.6, 1.1) 0.10
Other 61.5 (29.8,
92.4)
66.9 (45.9,
86.3)
5.4 (-37.0, 47.7) 0.80 80.0 (52.5,
96.9)
49.5 (24.3,
81.3)
-30.5 (-70.2, 9.2) 0.13
Wht+Hisp
+Oth
33.6 (23.7,
46.2)
62.2 (51.7,
72.6)
28.6 (13.1, 44.0) <0.01 80.7 (76.1,
85.0)
72.2 (67.1,
77.0)
-8.6 (-15.3, -1.8) 0.01
Age 18–24 years 25.0 (3.9, 87.2) 50.9 (39.1,
67.6)
25.9 (-19.5, 71.3) 0.26 80.8 (64.3,
92.8)
75.1 (61.5,
86.8)
-5.7 (-25.4, 14.1) 0.58
25–34 years 46.2 (40.0,
52.8)
52.1 (46.8,
57.6)
5.9 (-2.5, 14.3) 0.17 75.5 (68.8,
81.8)
69.3 (62.6,
75.9)
-6.2 (-15.5, 3.2) 0.20
35–87 years 39.0 (35.0,
43.3)
62.7 (58.9,
66.5)
23.7 (18.1, 29.4) <0.01 78.4 (74.1,
82.5)
68.3 (63.5,
73.0)
-10.2 (-16.5, -3.8) <0.01
HIV risk MSM 38.2 (33.0,
44.0)
61.9 (56.9,
66.9)
23.7 (16.3, 31.1) <0.01 81.9 (76.3,
86.9)
65.1 (58.7,
71.4)
-16.8 (-25.1, -8.5) <0.01
Heterosexual 43.5 (38.9,
48.5)
56.7 (52.6,
60.9)
13.2 (6.9, 19.6) <0.01 75.9 (71.1,
80.4)
71.5 (66.6,
76.2)
-4.4 (-11.1, 2.3) 0.20
Other 39.9 (28.2,
54.2)
56.8 (44.4,
69.8)
16.9 (-1.5, 35.3) 0.07 70.6 (55.6,
84.2)
70.2 (54.3,
84.6)
-0.4 (-22.0, 21.1) 0.97
Time since
HIV
diagnosis
< 1 year 39.5 (27.7,
54.1)
51.3 (38.9,
65.0)
11.8 (-7.0, 30.6) 0.22 80.8 (65.2,
92.4)
77.1 (63.0,
88.7)
-3.8 (-23.1, 15.6) 0.70
1–5 years 40.9 (35.5,
46.7)
59.4 (54.6,
64.3)
18.5 (11.1, 26.0) <0.01 78.1 (71.8,
83.8)
74.4 (67.9,
80.4)
-3.7 (-12.4, 5.0) 0.40
6–10 years 38.7 (32.4,
45.8)
51.2 (45.3,
57.4)
12.5 (3.4, 21.5) 0.01 77.9 (71.0,
84.1)
66.1 (58.7,
73.4)
-11.8 (-21.8, -1.9) 0.02
> 10 years 44.0 (37.6,
51.0)
66.6 (60.8,
72.3)
22.6 (13.8, 31.5) <0.01 76.5 (70.3,
82.2)
64.3 (57.9,
70.8)
-12.1 (-20.9, -3.3) 0.01
Notes. Other race/ethnicity includes American Indian/Alaska Native, Asian, Pacific Islander/Native Hawaiian, multiple races, and not specified. Other HIV risk includes
injection drug use, MSM who inject drugs, hemophilia, transfusion, perinatal, and not specified. Hisp = Hispanic. MSM = men who have sex with men. N = total
patients in study period. Oth = Other. Wht = White.
Time since HIV diagnosis was assessed at index clinic visit date.
https://doi.org/10.1371/journal.pone.0204599.t005
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(both p< 0.01). Significant increases were observed among blacks (9.7 percentage points,
p< 0.01), Hispanics (18.1 percentage points, p = 0.03), whites (9.5 percentage points,
p< 0.01), and persons of ‘other’ race or ethnicity (28.7 percentage points, p = 0.01). There
were significant increases (p< 0.01) among persons 18–34 years of age (14.3 percentage
points) and persons 35–87 years of age (8.2 percentage points). Treatment initiation increased
between study periods among persons reporting heterosexual behavior (7.5 percentage points,
p< 0.01), male-to-male sex (11.4 percentage points, p< 0.01), and persons reporting ‘other’
risk behaviors (14.1 percentage points, p = 0.02). Significant increases were found among
those diagnosed <1 year (23.1 percentage points, p< 0.01), 1–5 years (8.0 percentage points,
p< 0.01), 6–10 years (6.5 percentage points, p = 0.03), and>10 years (7.4 percentage points,
p = 0.01) ago who were exposed to the intervention.
Differences in retention in HIV care, although observed in the anticipated direction for
both sites combined (1.4 percentage point increase), were not statistically significant and did
not differ substantially by site (Table 3). Retention increased 28.0 percentage points between
study periods for patients in the ‘other’ racial category. Although the number of patients in
this sub-group was small, this difference was statistically significant (p = 0.03). No statistically
significant differences were observed when examined across sex/gender, remaining race/eth-
nicity categories, age, HIV risk, or time since HIV diagnosis.
Viral suppression was the primary measure of medication adherence. At Huntsville and
Atlanta combined, viral suppression improved 6.0 percentage points (p< 0.01) between study
periods. (Table 4) However, viral suppression in Atlanta increased by 17.5 percentage points
(p< 0.01), but decreased in Huntsville by 8.6 percentage points (p< 0.01). In Atlanta, all of
the percentage point changes for subgroups were increasing between study periods. Significant
increases were observed for patients who were male or female; black, Hispanic, or white;
between 35–87 years old; had heterosexual or male-to-male sexual risk; and were diagnosed
one or more years ago. (Table 5) Conversely, in Huntsville, all of the percentage point changes
for subgroups were decreasing between study periods. Significant decreases were observed for
patients who were female or transgender; black or Hispanic; between 35–87 years old; had
male-to-male sexual risk; and were diagnosed six or more years ago.
Similar findings were observed with respect to the secondary measure of laboratory-con-
firmed undetectable viral load. At both sites combined, undetectable viral load improved 3.8
percentage points (p = 0.03) between study periods. (Table 6) The sites again had divergent
results. Undetectable viral load in Atlanta improved by 15.2 percentage points (p< 0.01), but
dropped in Huntsville by 7.6 percentage points (p = 0.01). Again in Atlanta, all of the percent-
age point changes for subgroups were increasing between study periods. (Table 7) Significant
increases were observed for patients who were male or female; black; between 25–34 or 35–87
years old; for any transmission risk category; and for any time since diagnosis. Conversely, in
Huntsville, all of the percentage point changes for subgroups were decreasing between study
Table 6. Proportion of medication adherence among patients attending HIV clinics in two U.S. cities as measured by laboratory-confirmed undetectable HIV viral
load (< 50 copies/ml) at 183 days or 6 months, August 1, 2015-March 31, 2017.
Comparison Intervention Percentage Point Change, %
(95% CI)
p-value
Characteristic Category % (95% CI) % (95% CI)
All patients, N — 1980 2023 — —
Clinic location Combined 36.7 (34.2, 39.4) 40.6 (38.2, 43.0) 3.8 (0.3, 7.4) 0.03
Atlanta 9.7 (7.8, 12.0) 24.9 (22.3, 27.7) 15.2 (11.8, 18.6) <0.01
Huntsville 73.4 (69.6, 77.0) 65.8 (61.9, 69.6) -7.6 (-12.9, -2.3) 0.01
https://doi.org/10.1371/journal.pone.0204599.t006
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periods. Significant decreases were observed for patients who were female or transgender;
black or Hispanic; between 35–87 years old; had male-to-male sexual risk; and were diagnosed
6–10 years ago.
Table 7. Proportion of medication adherence among patients attending HIV clinics in two cities as measured by laboratory-confirmed undetectable HIV viral load
(< 50 copies/ml) at 183 days or 6 months, August 1, 2015-March 31, 2017, by subgroups of patient characteristics.
Atlanta Huntsville
Comparison Intervention Percentage Point
Change CI)
p-value Comparison Intervention Percentage Point
Change
p-value
Characteristic Category % (95% CI) % (95% CI) % (95% % (95% CI) % (95% CI) % (95% CI)
Patients, N — 1327 1302 — — 653 721 — —
Clinic location — 9.7 (7.8, 12.0) 24.9 (22.3,
27.7)
15.2 (11.8, 18.6) <0.01 74.0 (69.6,
77.0)
65.8 (61.9,
69.6)
-7.6 (-12.9, -2.3) 0.01
Sex/gender Male 7.7 (5.7, 10.2) 23.9 (21.0,
27.1)
16.3 (12.5, 20.0) <0.01 71.3 (66.8,
75.6)
68.5 (64.1,
72.8)
-2.8 (-9.0, 3.4) 0.37
Female 16.1 (11.7,
22.0)
28.0 (22.5,
34.6)
11.9 (4.0, 19.8) <0.01 78.8 (71.8,
85.1)
57.4 (49.3,
65.7)
-21.5 (-32.1,-10.8) <0.01
Transgender 0.0 (0.0, 33.6) 28.9 (13.2,
56.3)
28.9 (0.5, 57.3) 0.05 100 (100, 100) 63.6 (37.3,
88.8)
-36.4 (-64.8, -7.9) 0.01
Race/
ethnicity
Black, non-
Hisp
9.9 (7.9, 12.4) 25.0 (22.4,
28.0)
15.1 (11.6, 18.7) <0.01 69.9 (64.3,
75.4)
61.6 (55.9,
67.3)
-8.3 (-16.3, -0.3) 0.04
Hispanic 0.0 (0.0, 24.7) 19.0 (7.6, 43.1) 19.0 (-2.5, 40.6) 0.08 90.8 (78.6,
97.5)
66.7 (52.0,
80.7)
-24.1 (-41.8, -6.5) 0.01
White, non-
Hisp
10.2 (4.0, 25.0) 25.7 (15.1,
41.7)
15.5 (-0.7, 31.8) 0.06 76.0 (70.5,
81.1)
71.0 (65.4,
76.4)
-5.0 (-12.6, 2.7) 0.20
Other 10.0 (1.5, 52.7) 24.3 (10.8,
49.2)
14.3 (-12.1, 40.7) 0.29 76.7 (47.1,
96.4)
59.6 (32.6,
87.5)
-17.1 (-58.5, 24.3) 0.42
Wht+Hisp
+Oth
7.5 (3.2, 17.2) 23.7 (15.9,
34.3)
16.1 (5.0, 27.3) <0.01 77.5 (72.6,
82.1)
69.4 (64.2,
74.5)
-8.1 (-15.1, -1.1) 0.02
Age 18–24 years 0.0 (0.0, 70.8) 13.0 (5.6, 28.7) 13.0 (-30.8, 56.8) 0.56 73.7 (56.7,
88.1)
68.2 (53.9,
81.6)
-5.5 (-27.2, 16.3) 0.62
25–34 years 5.5 (3.2, 9.2) 18.5 (14.8,
23.2)
13.1 (8.0, 18.2) <0.01 70.8 (63.8,
77.6)
65.1 (58.1,
71.9)
-5.8 (-15.6, 4.0) 0.25
35–87 years 11.7 (9.2, 14.7) 29.1 (25.7,
32.8)
17.4 (12.9, 21.9) <0.01 74.4 (69.8,
78.8)
65.8 (60.9,
70.6)
-8.7 (-15.3, -2.0) 0.01
HIV risk MSM 14.4 (10.9,
18.8)
29.6 (25.2,
34.5)
15.2 (9.1, 21.3) <0.01 77.1 (71.0,
82.6)
62.0 (55.5,
68.5)
-15.1 (-23.8, -6.3) <0.01
Heterosexual 6.6 (4.5, 9.4) 20.9 (17.8,
24.5)
14.3 (10.2, 18.5) <0.01 72.0 (67.0,
76.8)
67.6 (62.7,
72.5)
-4.3 (-11.4, 2.7) 0.22
Other 7.3 (2.8, 18.5) 33.9 (23.3,
47.6)
26.6 (12.6, 40.6) <0.01 65.4 (50.3,
80.0)
70.2 (54.3,
84.6)
4.8 (-17.1, 26.7) 0.67
Time since
HIV
diagnosis
< 1 year 5.8 (1.9, 16.8) 19.8 (11.6,
32.5)
14.0 (2.0, 26.0) 0.02 72.2 (55.5,
86.8)
69.9 (55.2,
83.4)
-2.3 (-24.2, 19.5) 0.83
1–5 years 5.4 (3.4, 8.7) 23.2 (19.4,
27.7)
17.8 (12.9, 22.7) <0.01 74.1 (67.5,
80.2)
69.3 (62.6,
75.8)
-4.8 (-14.0, 4.4) 0.31
6–10 years 11.8 (8.1, 17.1) 20.2 (15.8,
25.6)
8.4 (1.8, 15.0) 0.01 75.5 (68.3,
82.0)
63.8 (56.3,
71.3)
-11.6 (-21.9, -1.4) 0.03
> 10 years 14.7 (10.6,
20.2)
33.2 (27.9,
39.3)
18.5 (11.1, 26.0) <0.01 71.0 (64.5,
77.2)
62.3 (56.1,
69.1)
-8.4 (-17.6, 0.7) 0.07
Notes. Other race/ethnicity includes American Indian/Alaska Native, Asian, Pacific Islander/Native Hawaiian, multiple races, and not specified. Other HIV risk includes
injection drug use, MSM who inject drugs, hemophilia, transfusion, perinatal, and not specified. Hisp = Hispanic. MSM = men who have sex with men. N = total
patients in study period. Oth = Other. Wht = White.
Time since HIV diagnosis was assessed at index clinic visit date.
https://doi.org/10.1371/journal.pone.0204599.t007
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Discussion
In our evaluation of the TCOM video, we found a significant overall increase in the percentage
of treatment initiators among patients who visited the sites while the video played and posters
were displayed (intervention condition), compared to patients who visited without the video
and posters (comparison condition). The overall positive change in treatment initiation also
was observed in sub-group analyses of demographic (i.e., sex, race/ethnicity, age) and behav-
ioral characteristics (i.e., HIV risk, time since HIV diagnosis). The nature of the study design
allows us to draw conclusions about association but not causation. Given that TCOM featured
multiple vignettes that modeled PWH of diverse racial/ethnic backgrounds and sexual orienta-
tions, it is not surprising that the video showed evidence of changing behavior among a hetero-
geneous patient population. However, the overall effects for retention in HIV care were
statistically non-significant. Medication adherence, measured by viral suppression and unde-
tectable viral load, was significantly greater during the intervention period than the compari-
son period in Atlanta and both sites combined. Other co-occurring factors may have
contributed to observed results, although their potential effect is unclear. For example, the
findings from the Strategic Timing of Antiretroviral Therapy (START) study, which showed
Fig 1. Flow diagram of Taking Care of Me study subjects, August 1, 2015 –March 31, 2017. The 10-month study period for August 1, 2015 to
May 31, 2016 was the historical comparison condition. The 10-month study period from June 1, 2016 to March 31, 2017 was the intervention
condition where all patients attending two HIV clinics were exposed to the Taking Care of Me video.
https://doi.org/10.1371/journal.pone.0204599.g001
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the benefit of early ART initiation, were published in August 2015. [1] START’s results were
widely known prior to publication and likely integrated in clinical practice before our study’s
comparison period. Also, HIV treatment guideline recommendation to initiate ART for all
PWH was upgraded to the highest level (i.e., A1) in January 2016. [18] Finally, health insur-
ance coverage increased nationwide during the study period; however, most PWH are Medic-
aid-eligible. Alabama and Georgia are not Medicaid expansion states, so increased national
Medicaid coverage likely had no impact on the numbers of PWH attending the study clinics.
Unlike Atlanta, Huntsville’s adherence results were negative. The reason is unclear. We
were unable to explore influences of socioeconomic status, educational attainment, or health
insurance coverage because the study did not collect these EMR data. Stratifying by race/eth-
nicity, age, HIV risk, and time since HIV diagnosis did not explain the difference between
sites. Sub-group analyses of adherence in Huntsville showed negative results across all groups,
suggesting systemic (e.g., clinic hours) or environmental (e.g., local policies) factors at work.
We contacted the Huntsville clinic to inquire about any such changes between study condi-
tions. The Huntsville clinic confirmed there had been a 23.5% increase in the number of new
patients during the intervention period but reported no environmental, political, policy, or
other changes in the clinic or Huntsville that could have contributed to the observed interven-
tion effects (S3 Appendix). It is highly probable that the Huntsville clinic patients who were
new to HIV treatment in the intervention condition did not have time to become virally sup-
pressed during the study measurement period. If we had used a less stringent medication
adherence measure (e.g., any viral load suppression within study period), the results may have
been higher. Ceiling effects also may have contributed to the between-site difference. Hunts-
ville had 77.7% suppression and 73.4% undetectable proportions during the comparison
period; these proportions were only 41.1% and 9.7%, respectively, in Atlanta. Thus, Huntsville
had less room for improvement.
The results presented in this paper extend the findings of Warner et al. (2008) [13] by showing
that a video-based intervention focused on HIV treatment can be effective at improving HIV clin-
ical outcomes. Having an effective tool that can be easily delivered in a waiting room affords a
high degree of audience-targeting with relatively low effort. As an effective approach to supporting
improved HIV clinical outcomes, this intervention has the potential to be widely disseminated to
HIV clinics and other appropriate settings. Additionally, it is reasonable to expect that the accept-
ability among patients and clinics seen with SITC [19] would be true of TCOM.
Video as an intervention tool continues to be prominent in current public health
approaches. [20] TCOM represents the first stand-alone video-based intervention we are
aware of that is effective at improving HIV-related health outcomes for PWH. The relative
overall change in treatment initiation (i.e., starting a new behavior) for TCOM is comparable
to the level of change in incident STDs (i.e., resulting from adopting new behaviors) for SITC
(10%). [13] Although video-based intervention effect sizes may be modest when compared to
those achieved from more resource-intensive interventions, video-based interventions deliver
their content consistently and can be scaled more efficiently, because they are rapid to dissemi-
nate, easy to implement, and inexpensive to sustain. For example, 260 agencies initiated V/V
in the first 20 months of its availability [21], and over 2100 clinics requested SITC in its first 15
months. [19] TCOM has the potential to be an important addition to the V/V and SITC set of
videos. The time and resources required for rigorous evaluation are barriers to developing and
evaluating new videos, and changes in societal norms and advances in HIV prevention and
treatment may influence a video’s continued relevance. Given the relative scarcity of public
health resources, the trade-offs between faster dissemination and lengthy evaluation should be
considered. By forgoing intensive evaluation of videos that follow successful models, new pre-
vention videos could be made available sooner. This could likely have a significant positive
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impact on the health of PWH, reduce future health care costs, and help achieve national HIV
prevention, care, and treatment goals.
Our study suggests that there were significant intervention effects among specific sub-groups
for treatment initiation and medication adherence outcomes. For treatment initiation, most
demographic and behavioral characteristic groups appeared to have benefited from TCOM expo-
sure. It is plausible that the observed intervention effects are due partly to the video’s embedded
prevention messages and its appeal to a wide patient audience. However, the intervention may
have had an indirect effect if clinicians watched the video and learned how to effectively dialogue
with patients about the benefits of early treatment. For both measurement levels of medication
adherence, males, blacks, and older patients appeared to have benefited from exposure to TCOM.
The significant intervention effects for both adherence measures seen among Atlanta, but not
Huntsville, patients are difficult to explain. In addition to a possible ceiling effect, it is probable
that Huntsville’s simultaneous increases in patient population and treatment initiation temporarily
increased clinic-wide viral load levels. Retention in care is a difficult outcome to measure in a stan-
dard way. HRSA’s definition needed to be adapted for this study design, and the study’s 10-month
intervention period may not have been enough time to see the full effects of the intervention.
Study limitations
The study had a number of limitations. First, it was not possible to randomly assign patients to
one or the other study condition; therefore, the findings may be subjected to bias. Second, the
quasi-experimental study design is subject to secular trends (e.g., health insurance enrollment
periods). Third, we did not measure exposure to the video, so we do not know whether or not
patients paid attention to the video or saw it multiple times. Fourth, Huntsville played the
Spanish-captioned video uninterrupted, while Atlanta played the English-captioned video
with minor interruptions and some competition from another television. Finally, the sample
size was affected by the exclusion of Miami’s data.
Our study design also had several strengths, especially with regard to rapid intervention
development and evaluation to promote improved HIV outcomes. Similar to our previous
video-based intervention studies in STD clinics [10, 11, 13], this evaluation was conducted
under clinic conditions. By integrating TCOM into the waiting room environment of two HIV
clinics, we were able to evaluate intervention effectiveness in increasing treatment initiation
and medication adherence among a relatively large clinic population of PWH. Our evaluation
used medical outcomes and routinely collected EMR data rather than behavioral outcomes
and self-reported data. Consequently, our overall treatment initiation and medication adher-
ence findings are likely generalizable to other HIV-infected patients at these and other clinics
with similar patient characteristics. Similar to our previous work [13], our study design
included all clinic patients, thereby avoiding threats to external validity (e.g., low or differential
participation rates) inherent in studies using only willing participants. Given that patients
were not actively enrolled, they did not perceive the video as part of a study, and biases associ-
ated with active study participation were avoided.
We found that a brief video-based behavioral intervention in a clinic setting was effective at
improving HIV-related outcomes among PWH. Due to its ease of delivery in a waiting room
setting and low cost to sustain, it is important for HIV clinics and other healthcare settings
serving PWH to consider integrating the TCOM video into standard clinical practice.
Supporting information
S1 Appendix. Study protocol.
(DOCX)
Effects of brief video on HIV patient treatment initiation and adherence
PLOS ONE | https://doi.org/10.1371/journal.pone.0204599 October 5, 2018 13 / 16
S2 Appendix. TREND checklist.
(PDF)
S3 Appendix. Huntsville clinic communication.
(PDF)
S1 Dataset. Taking Care of Me de-identified study data file.
(ZIP)
Acknowledgments
The study group thanks the project technical consultants who provided input and review of the
video storylines and scripts, the videographer (Jesse Moss of Mile End Films West, http://www.
mileendfilms.com), the HIV clinics (Thrive Alabama, Huntsville, AL; Borinquen Medical Cen-
ter, Miami, FL; and HIV Primary Care Clinic, Atlanta, GA) and their staff which implemented
the intervention and shared their data, and the patients of these clinics who saw the video.
Disclaimer: The findings and conclusions in this report are those of the authors and do not
necessarily represent the official position of the Centers for Disease Control and Prevention or
the Health Resources and Services Administration.
Author Contributions
Conceptualization: Mary Spink Neumann, Andrew D. Margolis, Craig B. Borkowf, C. Kevin
Malotte, Cornelis A. Rietmeijer, Lydia O’Donnell, Susan Robilotto, Jorge A. Montoya, Jef-
frey D. Klausner.
Data curation: Aaron Plant, Marjan Javanbakht.
Formal analysis: Mary Spink Neumann, Craig B. Borkowf.
Funding acquisition: Mary Spink Neumann, Andrew D. Margolis, C. Kevin Malotte, Jorge A.
Montoya.
Investigation: Aaron Plant, Athi Myint-U.
Methodology: Mary Spink Neumann, Aaron Plant, Andrew D. Margolis, C. Kevin Malotte,
Cornelis A. Rietmeijer, Susan Robilotto.
Project administration: Mary Spink Neumann, Aaron Plant, Andrew D. Margolis, Stephen
A. Flores.
Resources: Mary Spink Neumann.
Software: Craig B. Borkowf, Marjan Javanbakht.
Supervision: Mary Spink Neumann, Aaron Plant, Stephen A. Flores.
Validation: Mary Spink Neumann, Craig B. Borkowf, Marjan Javanbakht.
Visualization: Aaron Plant, Craig B. Borkowf.
Writing – original draft: Mary Spink Neumann, Aaron Plant, Andrew D. Margolis, Craig B.
Borkowf, C. Kevin Malotte, Cornelis A. Rietmeijer, Stephen A. Flores, Lydia O’Donnell,
Athi Myint-U.
Writing – review & editing: Mary Spink Neumann, Aaron Plant, Andrew D. Margolis, Craig
B. Borkowf, C. Kevin Malotte, Cornelis A. Rietmeijer, Stephen A. Flores, Lydia O’Donnell,
Susan Robilotto, Athi Myint-U, Jorge A. Montoya, Marjan Javanbakht, Jeffrey D. Klausner.
Effects of brief video on HIV patient treatment initiation and adherence
PLOS ONE | https://doi.org/10.1371/journal.pone.0204599 October 5, 2018 14 / 16
References
1. INSIGHT START Study Group. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation
of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015; 373(9): 795–807.
https://doi.org/10.1056/NEJMoa1506816 PMID: 26192873.
2. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of
HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365(6): 493–505. https://doi.org/
10.1056/NEJMoa1105243 PMID: 21767103
3. Gu¨nthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, et al. Antiretroviral drugs for treat-
ment and prevention of HIV Infection in adults: 2016 recommendations of the International Antiviral
Society-USA Panel. JAMA. 2016; 316(2): 191–210. https://doi.org/10.1001/jama.2016.8900 PMID:
27404187.
4. World Health Organization. Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and
Care for Key Populations—2016 Update. 2016. Available from: http://apps.who.int/iris/bitstream/10665/
246200/1/9789241511124-eng.pdf?ua=1.
5. Office of National AIDS Policy. National HIV/AIDS Strategy for the United States—Updated to 2020.
2015. Available from: https://www.hiv.gov/sites/default/files/nhas-update.pdf.
6. Centers for Disease Control and Prevention. More People with HIV Have the Virus Under Control—
Press Release. 2017. Available from: https://www.cdc.gov/nchhstp/newsroom/2017/2017-HIV-
Continuum-Press-Release.html.
7. Centers for Disease Control and Prevention. Compendium of Evidence-Based Interventions and Best
Practices for HIV Prevention. Website. 2017. Available from: https://www.cdc.gov/hiv/research/
interventionresearch/compendium/index.html
8. Centers for Disease Control and Prevention. High-Impact HIV Prevention, CDC’s Approach to Reduc-
ing HIV Infections in the United States. August 2011. Available from: https://www.cdc.gov/hiv/pdf/
policies_NHPC_Booklet.pdf
9. Besera GT, Cox S, Malotte CK, Rietmeijer CA, Klausner JD, O’Donnell L, et al. Assessing patient expo-
sure to a video-based intervention in STD clinic waiting rooms. Health Promotion Practice. 2016: 17(5):
731–738. https://doi.org/10.1177/1524839916631537 PMID: 27091608.
10. Neumann MS, O’Donnell L, Doval AS, Schillinger J, Blank S, Ortiz-Rios E, et al. Effectiveness of the
VOICES/VOCES sexually transmitted disease/human immunodeficiency virus prevention intervention
when administered by health department staff: does it work in the "real world"? Sex Transm Dis. 2011;
38(2): 133–139. https://doi.org/10.1097/OLQ.0b013e3181f0c051 PMID: 20729794.
11. O’Donnell CR, O’Donnell L, San Doval A, Duran R, Labes K. Reductions in STD infections subsequent
to an STD clinic visit. Using video-based patient education to supplement provider interactions. Sex
Transm Dis. 1998; 25(3): 161–168. PubMed PMID: 9524995.
12. Sweat M, O’Donnell C, O’Donnell L. Cost-effectiveness of a brief video-based HIV intervention for Afri-
can American and Latino sexually transmitted disease clinic clients. AIDS. 2001; 15(6): 781–787.
PubMed PMID: 11371693.
13. Warner L, Klausner JD, Rietmeijer CA, Malotte CK, O’Donnell L, Margolis AD, et al. Effect of a brief
video intervention on incident infection among patients attending sexually transmitted disease clinics.
PLoS Medicine. 2008; 5(6): 919–27. https://doi.org/10.1371/journal.pmed.0050135 PMID: 18578564.
14. Gift TL, O’Donnell LN, Rietmeijer CA, Malotte KC, Klausner JD, Margolis AD, et al. The program cost of
a brief video intervention shown in sexually transmitted disease clinic waiting rooms. Sex Transm Dis.
2016; 43(1): 61–64. https://doi.org/10.1097/OLQ.0000000000000388 PMID: 26650999.
15. Carey MP, Senn TE, Walsh JL, Coury-Doniger P, Urban MA, Fortune T, et al. Evaluating a brief, video-
based sexual risk reduction intervention and assessment reactivity with STI clinic patients: Results from
a randomized controlled trial. AIDS Behav. 2015: 19(7): 1228–1246. https://doi.org/10.1007/s10461-
014-0960-3 PMID: 25433653.
16. Myint U A, Bull S, Greenwood GL, Patterson J, Rietmeijer CA, Vrungos S, et al. Safe in the City: devel-
oping an effective video-based intervention for STD clinic waiting rooms. Health Promot Pract 2010; 11
(3): 408–417. https://doi.org/10.1177/1524839908318830 PMID: 18544663.
17. Health Resources and Services Administration. Ryan White HIV/AIDS Program Annual Client-Level
Data Report 2015. Published December 2016. Available from: http://hab.hrsa.gov/data/data-reports.
18. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral
agents in HIV-1-infected adults and adolescents. 2017. Department of Health and Human Services.
Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
19. Harshbarger CL, O’Donnell LN, Warner L, Margolis AD, Richardson DB, Novey SR, et al. Safe in the
City: effective prevention interventions for human immunodeficiency virus and sexually transmitted
Effects of brief video on HIV patient treatment initiation and adherence
PLOS ONE | https://doi.org/10.1371/journal.pone.0204599 October 5, 2018 15 / 16
infections. Am J Prev Med. 2012; 42(5): 468–472. https://doi.org/10.1016/j.amepre.2012.01.029 PMID:
22516486.
20. Neumann MS, Plant A, Margolis AD, Borkowf CB. Taking Care of Me: Educating and empowering per-
sons living with HIV. Presentation at American Public Health Association’s Global Film Festival, Atlanta,
GA, November 7, 2017.
21. Harshbarger C, Simmons G, Coelho H, Sloop K, Collins C. An empirical assessment of implementation,
adaptation, and tailoring: the evaluation of CDC’s National Diffusion of VOICES/VOCES. AIDS Educ
Prev. 2006; 18(4 Suppl A): 184–97. https://doi.org/10.1521/aeap.2006.18.supp.184 PMID: 16987099.
Effects of brief video on HIV patient treatment initiation and adherence
PLOS ONE | https://doi.org/10.1371/journal.pone.0204599 October 5, 2018 16 / 16
